M2-型丙酮酸激酶(PKM2)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Pyruvate kinase isozymes M2 (PKM2)
M2PK; PKM; M2-PK; PKM1; CTHBP; OIP3; PK3; PKM; TCB; THBP1; Pyruvate kinase muscle isozyme; Thyroid hormone-binding protein 1; Cytosolic thyroid hormone-binding protein; Pyruvate Kinase, Muscle
- 编号SEA588Ra
- 物种Rattus norvegicus (Rat,大鼠) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围0.47-30ng/mL
- 灵敏度最小可检测剂量小于等于0.21ng/mL.
- 样本类型Serum, plasma, tissue homogenates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 2873 ¥ 4104 ¥ 18468 ¥ 34884 ¥ 287280
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测M2-型丙酮酸激酶(PKM2),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的M2-型丙酮酸激酶(PKM2)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 88-99 | 95 |
EDTA plasma(n=5) | 90-97 | 94 |
heparin plasma(n=5) | 81-96 | 85 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的M2-型丙酮酸激酶(PKM2),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中M2-型丙酮酸激酶(PKM2)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 88-102% | 80-104% | 85-104% | 88-96% |
EDTA plasma(n=5) | 89-101% | 99-105% | 90-104% | 91-101% |
heparin plasma(n=5) | 78-97% | 85-104% | 99-105% | 89-104% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备;
2. 加样(标准品及样本)100µL,37°C孵育1小时;
3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
4. 洗板3次;
5. 加检测溶液B100µL,37°C孵育30分钟;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分钟;
8. 加终止液50µL,立即450nm读数。
实验原理
将M2-型丙酮酸激酶(PKM2)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的M2-型丙酮酸激酶(PKM2)与连接于固相载体上的抗体结合,然后加入生物素化的M2-型丙酮酸激酶(PKM2)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的M2-型丙酮酸激酶(PKM2)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。
增值服务
相关产品
编号 | 适用物种:Rattus norvegicus (Rat,大鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPA588Ra01 | M2-型丙酮酸激酶(PKM2)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA588Ra01 | M2-型丙酮酸激酶(PKM2)多克隆抗体 | WB; IHC; ICC; IP. |
FAA588Ra01 | 抗M2-型丙酮酸激酶(PKM2)多克隆抗体 | Flow cytometry. |
MAA588Ra21 | M2-型丙酮酸激酶(PKM2)单克隆抗体 | WB; IHC; ICC; IP. |
SEA588Ra | M2-型丙酮酸激酶(PKM2)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA588Ra | M2-型丙酮酸激酶(PKM2)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Cancer Research | Antigen Presentation by Dendritic Cells in Tumors Is Disrupted by Altered Metabolism that Involves Pyruvate Kinase M2 and Its Interaction with SOCS3 [AACR: 70189] |
Molecular BioSystems | Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer [Pubmed:25483567] |
Tumour Biol | M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh’s ESCC and promotes proliferation and migration of ESCC cells [PubMed: 26404132] |
Oncotarget | Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis [Pubmed:29707118] |
Journal of Neurotrauma | Acteoside improves muscle atrophy and motor function by inducing new myokine secretion in chronic spinal cord injury [Pubmed: 30318996] |
Cell Reports | Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway [Pubmed: 32049010] |
Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) [] | |
Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins [] |
Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression [34376212] |
Life (Basel) | Putative Association between Low Baseline Gene Expression in the Peripheral Blood and Clinical Remission in Rheumatoid Arthritis Patients Treated with Tofacitinib [34947916] |